Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 10, 2017, by Perrigo Company plc. The filing primarily addresses a change in the Company's reporting segments to better align with its organizational structure. Additionally, the Company reaffirmed its fiscal year-end change to a calendar year (January 1 to December 31), effective January 1, 2016.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. Instead, it references Exhibit 99.1, which contains recast historical financial information for calendar years 2013 through 2016 and various quarterly periods. The Company utilizes non-GAAP measures to supplement GAAP reporting, including adjusted gross profit, adjusted operating income, and adjusted net income, to exclude items such as impairment charges, restructuring charges, and acquisition-related costs.
Material Changes
The Company has reorganized its reporting segments as follows:
- Consumer Healthcare Americas: Comprises the legacy U.S., Mexico, and Canada consumer healthcare business (OTC, contract, infant formula, and animal health).
- Consumer Healthcare International: Comprises the legacy Branded Consumer Healthcare segment, now including consumer-focused businesses in the U.K., Australia, and Israel, plus the U.K. liquids licensed products business (previously in Prescription Pharmaceuticals).
- Prescription Pharmaceuticals: Comprises the legacy U.S. Prescription Pharmaceuticals business.
- Specialty Sciences: Continues to comprise royalties from Tysabri.
- Other: Continues to comprise the legacy Active Pharmaceutical Ingredients (API) business.
The Company states that these segment changes and the prior fiscal year-end change have no impact on the Company's historical consolidated financial position, results of operations, or cash flows. Selected financial statements have been recast to aid comparability.
Guidance, Outlook, and Corporate Governance
The filing does not contain specific forward-looking guidance or management commentary on future financial performance. However, it notes that management uses adjusted non-GAAP measures for planning, forecasting, and determining compensation.
Under Item 8.01, the Company disclosed an amendment to its insider trading policy effective August 2, 2016. The amended policy prohibits executive officers and directors from pledging Company securities as collateral for loans and prohibits all employees and directors from engaging in short sales, short sales against the box, or hedging/monetization transactions regarding Company securities.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific recast financial metrics for the periods ending December 31, 2016, and prior years.
- Verify the reconciliation between GAAP and non-GAAP measures provided in the report to understand the impact of excluded items (e.g., restructuring, impairments).
- Confirm the impact of the new segment structure on future quarterly reporting and comparability with historical data.
- Review the Transition Report on Form 10-KT and subsequent Form 10-Q filings for detailed operational results.